Dianthus Therapeutics (DNTH) Earnings Date & Reports

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

DNTH is expected to report earnings to fall 19.58% to -303 cents per share on September 18

Dianthus Therapeutics DNTH Stock Earnings Reports

Q2'23

Est.

$-3.04

Q3'23

Missed

by $3.22

Q1'23

Missed

by $0.07

Q4'22

Missed

by $0.02

Q3'22

Beat

by $0.02

The last earnings report on November 09 showed earnings per share of -377 cents, missing the estimate of -56 cents. With 949.11K shares outstanding, the current market capitalization sits at 573.76M.

View a ticker or compare two or three

Compare

DNTH